{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:08:55Z","timestamp":1784167735371,"version":"3.55.0"},"reference-count":64,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although most tumors in patients with acromegaly are benign and are cured or controlled by surgery and\/or first-generation somatostatin receptor ligands therapy, some can behave more aggressively and are resistant to these standard therapies. Acromegaly, if left untreated, is a rare and chronic disorder, commonly caused by a GH-producing pituitary adenoma and is associated with significant comorbidities and an increased mortality. Transsphenoidal surgery is considered the mainstay of acromegaly management, but medical therapy has an increasingly important role. However, disease activity is not fully controlled in a significant number of patients treated with surgery and\/or high-dose first-generation somatostatin receptor ligand monotherapy. In these circumstances, therefore, repeated surgery, second-line medical therapy, and radiotherapy, alone or combined as multimodal therapeutic strategies should be considered, in a patient-centered perspective.<\/jats:p>","DOI":"10.1210\/clinem\/dgac037","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T17:26:37Z","timestamp":1643390797000},"page":"1759-1766","source":"Crossref","is-referenced-by-count":23,"title":["Approach to the Patient With Treatment-resistant Acromegaly"],"prefix":"10.1210","volume":"107","author":[{"given":"Eva C","family":"Coopmans","sequence":"first","affiliation":[{"name":"Department of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center , 3000 CA Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart J","family":"van der Lely","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center , 3000 CA Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7698-0282","authenticated-orcid":false,"given":"Sebastian J C M M","family":"Neggers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus University Medical Center , 3000 CA Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"1","key":"2022072605384332700_CIT0001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.01824","article-title":"Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs","volume":"152","author":"Petrossians","year":"2005","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2022072605384332700_CIT0002","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest."},{"issue":"4","key":"2022072605384332700_CIT0003","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022072605384332700_CIT0004","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"11","key":"2022072605384332700_CIT0005","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an Endocrine Society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022072605384332700_CIT0006","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: a Dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022072605384332700_CIT0007","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/neuros\/nyx020","article-title":"Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors","volume":"81","author":"Babu","year":"2017","journal-title":"Neurosurgery."},{"issue":"4","key":"2022072605384332700_CIT0008","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022072605384332700_CIT0009","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ando.2012.05.001","article-title":"The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly","volume":"73","author":"Petrossians","year":"2012","journal-title":"Ann Endocrinol (Paris)."},{"issue":"1","key":"2022072605384332700_CIT0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1385\/ENDO:28:1:067","article-title":"Treatment of pituitary tumors: surgery","volume":"28","author":"Buchfelder","year":"2005","journal-title":"Endocrine."},{"issue":"1","key":"2022072605384332700_CIT0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000441980","article-title":"Novel techniques in the surgical treatment of acromegaly: applications and efficacy","volume":"103","author":"Buchfelder","year":"2016","journal-title":"Neuroendocrinology."},{"issue":"4","key":"2022072605384332700_CIT0012","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.nec.2012.06.005","article-title":"Management options for persistent postoperative acromegaly","volume":"23","author":"Mathioudakis","year":"2012","journal-title":"Neurosurg Clin N Am."},{"issue":"5","key":"2022072605384332700_CIT0013","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"2022072605384332700_CIT0014","doi-asserted-by":"crossref","first-page":"(4):636-646","DOI":"10.4158\/EP.17.4.636","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract."},{"issue":"1","key":"2022072605384332700_CIT0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary."},{"issue":"16","key":"2022072605384332700_CIT0016","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med."},{"issue":"9295","key":"2022072605384332700_CIT0017","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely A","year":"2001","journal-title":"Lancet."},{"issue":"4","key":"2022072605384332700_CIT0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1530\/EJE-16-0008","article-title":"Treatment with high doses of pegvisomant in 56 patients with acromegaly: experience from ACROSTUDY","volume":"175","author":"van der Lely A","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2022072605384332700_CIT0019","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022072605384332700_CIT0020","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2018-02281","article-title":"Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies","volume":"104","author":"Feola","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022072605384332700_CIT0021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2022072605384332700_CIT0022","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022072605384332700_CIT0023","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"12","key":"2022072605384332700_CIT0024","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022072605384332700_CIT0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2022072605384332700_CIT0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers","year":"2011","journal-title":"Growth Horm IGF Res."},{"issue":"9","key":"2022072605384332700_CIT0027","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022072605384332700_CIT0028","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022072605384332700_CIT0029","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"931","key":"2022072605384332700_CIT0030","first-page":"931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"11","key":"2022072605384332700_CIT0031","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022072605384332700_CIT0032","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr Disord."},{"issue":"6","key":"2022072605384332700_CIT0033","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1210\/jc.2018-01979","article-title":"How to position pasireotide LAR treatment in acromegaly","volume":"104","author":"Coopmans","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022072605384332700_CIT0034","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022072605384332700_CIT0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022072605384332700_CIT0036","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022072605384332700_CIT0037","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12020-020-02306-4","article-title":"Soluble Klotho: a possible predictor of quality of life in acromegaly patients","volume":"69","author":"Coopmans","year":"2020","journal-title":"Endocrine."},{"issue":"1","key":"2022072605384332700_CIT0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-016-1029-z","article-title":"Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment","volume":"54","author":"Luger","year":"2016","journal-title":"Endocrine."},{"issue":"13","key":"2022072605384332700_CIT0039","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-016-0615-y","article-title":"Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"76","author":"Samson","year":"2016","journal-title":"Drugs."},{"issue":"4","key":"2022072605384332700_CIT0040","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"2022072605384332700_CIT0041","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract."},{"issue":"1","key":"2022072605384332700_CIT0042","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000435776","article-title":"The role of radiotherapy in acromegaly","volume":"103","author":"Hannon","year":"2016","journal-title":"Neuroendocrinology."},{"issue":"3","key":"2022072605384332700_CIT0043","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/neuros\/nyaa054","article-title":"The impact of insulin-like growth factor index and biologically effective dose on outcomes after stereotactic radiosurgery for acromegaly: cohort study","volume":"87","author":"Graffeo","year":"2020","journal-title":"Neurosurgery."},{"issue":"3","key":"2022072605384332700_CIT0044","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/EJE-19-0784","article-title":"Fractionated radiotherapy and radiosurgery in acromegaly: analysis of 352 patients from the German Acromegaly Registry","volume":"182","author":"Knappe","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022072605384332700_CIT0045","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jc.2005-1616","article-title":"Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly","volume":"91","author":"Jenkins","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022072605384332700_CIT0046","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1210\/jcem.85.7.6699","article-title":"Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly","volume":"85","author":"Biermasz","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"2022072605384332700_CIT0047","first-page":"210","author":"Minniti","year":"2005"},{"issue":"11","key":"2022072605384332700_CIT0048","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1210\/jc.2009-1097","article-title":"ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly","volume":"94","author":"Sherlock","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022072605384332700_CIT0049","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev."},{"issue":"3","key":"2022072605384332700_CIT0050","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/JOE-17-0254","article-title":"AIP and the somatostatin system in pituitary tumours","volume":"235","author":"Ibanez-Costa","year":"2017","journal-title":"J Endocrinol."},{"issue":"4","key":"2022072605384332700_CIT0051","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022072605384332700_CIT0052","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000322040","article-title":"Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas","volume":"93","author":"Taboada","year":"2011","journal-title":"Neuroendocrinology."},{"issue":"3","key":"2022072605384332700_CIT0053","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tem.2013.11.003","article-title":"Somatostatin analogs: does pharmacology impact antitumor efficacy?","volume":"25","author":"Chalabi","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"2022072605384332700_CIT0054","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022072605384332700_CIT0055","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022072605384332700_CIT0056","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev."},{"issue":"5","key":"2022072605384332700_CIT0057","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab."},{"issue":"11","key":"2022072605384332700_CIT0058","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol."},{"issue":"3","key":"2022072605384332700_CIT0059","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe."},{"key":"2022072605384332700_CIT0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.humpath.2017.11.008","article-title":"High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs","volume":"72","author":"Kasajima","year":"2018","journal-title":"Hum Pathol."},{"issue":"6","key":"2022072605384332700_CIT0061","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4158\/EP14575.DSCR","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: management of acromegaly patients: what is the role of pre-operative medical therapy?","volume":"21","author":"Fleseriu","year":"2015","journal-title":"Endocr Pract"},{"issue":"Pt 9","key":"2022072605384332700_CIT0062","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/brain\/awp170","article-title":"At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists","volume":"132","author":"Abler","year":"2009","journal-title":"Brain."},{"key":"2022072605384332700_CIT0063","doi-asserted-by":"crossref","first-page":"101356","DOI":"10.1016\/j.ghir.2020.101356","article-title":"Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas","volume":"55","author":"Ozkaya","year":"2020","journal-title":"Growth Horm IGF Res."},{"issue":"1","key":"2022072605384332700_CIT0064","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac037\/42536654\/dgac037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/1759\/45061600\/dgac037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/6\/1759\/45061600\/dgac037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T05:39:33Z","timestamp":1658813973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/6\/1759\/6516806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,1,28]]},"published-print":{"date-parts":[[2022,5,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac037","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,1,28]]}}}